Near-term prospects for gene therapy

Near-term prospects for gene therapy Despite increasing attention to the potential of in vivo gene therapies, the near-term opportunities will continue to be ex vivo autologous treatments, according to executives at Somatix Therapy Corp.

"It's like bone marrow transplantation," said David Carter, president and CEO, in a meeting with BioCentury. "I think it's an effective business and that's how it will be regulated."

Anton Berns,

Read the full 700 word article

How to gain access

Continue reading with a
two-week free trial.